A recent Cochrane review confirms that magnesium sulfate infusion prevents cerebral palsy in premature infants. This life-changing intervention, costing approximately $7 per dose, has been recommended by the World Health Organization since 2015.
The Challenge: Inconsistent Global Access
Despite its proven effectiveness, magnesium sulfate remains inaccessible to many due to implementation challenges. The PReCePT program in England has made significant strides, promoting widespread use and reducing cerebral palsy cases.
Success Stories: PReCePT Program Impact
Elly Salisbury’s son Cormac, now 11, benefited from magnesium sulfate through PReCePT. “Every family deserves this chance…I hope health systems worldwide take inspiration from PReCePT’s success.”
Key Findings:
- Magnesium sulfate reduces cerebral palsy risk by 30%
- Implementation challenges persist globally
- PReCePT program expands to all NHS maternity units in England
- Estimated 385 fewer cerebral palsy cases between 2018-2023
Expert Insights:
“Preterm birth is the leading cause of brain injury and cerebral palsy…Magnesium sulfate is a potential game-changer.” – Karen Luyt, Professor in Neonatal Medicine
Future Directions:
- Improving implementation in lower-resource areas
- Ensuring equitable access worldwide
Take Action:
- Support global health initiatives promoting magnesium sulfate access
- Share success stories like Elly’s to raise awareness
Stay updated on global health breakthroughs and initiatives.
Share your thoughts: How can we ensure equitable access to magnesium sulfate worldwide?
